This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
Filter documents Clear search
FSRH CEU Statement: Response to recently published “Bridge-It” study by Cameron, et al - November 2020
The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.
“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.
FSRH CEU Response to study: Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme inducing antibiotics and hormonal contraceptives - August 2020
This statement is a response to a new paper published in BMJ Evidence Based Medicine Journal suggesting that antibiotics may lessen the effectiveness of hormonal contraception.
FSRH CEU Statement : New advice from the MHRA regarding cyproterone acetate: how does this affect prescribing of Co-cyprindiol/Dianette® for acne/hirsutism? July 2020
This statement is a response to new advice from the MHRA regarding use of cyproterone acetate and risk of meningioma.
AoMRC, BMA, NHS Confederation, NHS Providers, RCN and UNISON statement: Supporting the health and care workforce beyond COVID-19
This statement addresses the issues faced by the health and care workforce before and during the COVID-19 pandemic.
FSRH CEU: Provision of contraception by maternity services after childbirth during the Covid-19 Pandemic April 2020
FSRH CEU has produced an information sheet to support the provision of contraception by maternity services after childbirth during the Covid-19 outbreak.
FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions
At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.
FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak
During Covid19-related restriction in face-to-face contact with healthcare professionals, FSRH CEU offers the following clinical advice to support ongoing provision of effective contraception. Provision of effective contraception (this may be a bridging method in the short term) and emergency contraception are considered priority services.
This statement reviews and summarises the available evidence regarding the effect of contraception on weight. Looking at each method individually, the FSRH CEU advises clinicians regarding proven and theoretical associations between contraceptive options and weight/BMI.
FSRH CEU statement on antibiotic cover for urgent insertion of intrauterine contraception in women at high risk of STI (May 2019)
This statement provides guidance on antibiotic cover for urgent insertion of intrauterine contraception in women at high risk of STI. Download the full document here.